🔗 Share this article

As the United States continues making unprecedented revisions to its vaccine schedules, one figure appears somewhat surprisingly: Høeg, a Danish American sports physician and public health researcher who rose to prominence by casting doubt on Covid shots in the pandemic and has concentrated on potential fatalities following COVID-19 immunization in her short position at the US Food and Drug Administration (FDA).

Scheduled Overhauls to Childhood Immunization Program

Agency leaders planned to reveal radical changes to the childhood vaccine schedule in December, aligning the US with Denmark’s national calendar, it is understood – a major change that would place the US out of alignment with a large portion of the global community with little proof for benefit. This reveal has been postponed until the new year.

Instead of the top vaccines chief, Tracy Beth Høeg is set to speak at the meeting. She was newly appointed acting director of the FDA’s drug evaluation center, the fifth appointee to head the division this calendar year.

A Shift at the FDA

The acting appointment might represent a strengthened alliance between the drug and vaccine branches as Høeg and Dr. Prasad solidify control at the regulatory agency – and it signals a renewed priority upon dismantling long-standing vaccines at the FDA.

The new acting director has often pushed for halting some childhood vaccine recommendations in the US to become more like Denmark, a nation with universal health coverage and a number of inhabitants approximately the size of the state of Wisconsin.

In her initial public appearances, she has kept her attention on immunizations – typically the responsibility of Dr. Prasad, chief of the FDA’s CBER – as opposed to medication approval.

Concerns Over Qualifications

Dr. Høeg has no obvious experience in medication creation, oversight or management, which has been customary for former leaders of the biologics center. She has worked at the FDA as a top consultant to the agency head and CBER since spring.

“She appears not to have any of the qualifications” for leading the pharmaceutical oversight division, said Jonathan Howard. “She has not conducted a scientific study. She has no expertise in running a major agency. She lacks background in drug approvals.”

Former heads of CBER would “understand regulatory frameworks and the research of drug development”, commented Dr. Janet Woodcock. “Frankly, she lacks the kind of background that prior appointees who led CBER have had.”

This division has an immense workload at the agency, the former commissioner pointed out.

“Everybody just zeroes in on the novel medication approvals, but the generic drug division approves a multitude of generic medications. There’s a biologic copycat branch, OTC medication office and more, and every single one have to be supervised,” she noted. “The responsibility you overlook, that is the part that I always told people is going to cause problems.”

Additionally, a substantial management component to the job, which oversees more than 5,000 employees. “It is a huge leadership role, if you perform it correctly,” Woodcock added.

Agency Reaction and Disputed Programs

When asked about concerns about Høeg’s qualifications and whether this appointment indicates more teamwork among agency officials on immunizations, a press secretary said that the “concerns rely on incorrect premises”.

“This background aligns with the responsibilities of her role,” the official stated, citing the time Høeg spent counseling the agency head on “medication safety and oversight research, including computerized risk analysis and shot safety tracking”.

As acting director, Dr. Høeg assumes responsibility for the commissioner’s new fast-track approval initiative, a controversial one-day therapy clearance system that reportedly concerned her former heads. “How are these therapies being picked for this expedited pathway? Who makes the decisions?” Dr. Howard asked. “There is a lot of confidentiality going on at the regulatory body right now.”

In general, he said, “the FDA looks to be trending towards laxer oversight of all drugs, with the exception of vaccines.”

Public Past Work on Vaccines

Concerning vaccines, Høeg has a more documented, if problematic, past, some experts said. She published a research paper using unverified public submissions to determine the frequency of heart inflammation after COVID-19 vaccination. She counseled the state of Florida chief medical officer Dr. Joseph Ladapo, who allegedly have changed statistics to suggest COVID-19 vaccines are riskier than they are.

Part of her “desired changes” for the new federal leadership included revising rules for recently developed shots and ending “optional” immunizations, she remarked after the election on a audio program. At the agency, Høeg has allegedly suggested barring teenage boys from getting COVID-19 vaccinations.

“She’s an thorough true believer who begins with her preconceived notions and tailors the evidence to fit the evidence in a extremely deceptive, untruthful way,” Howard argued.

Taking Control and a “Revenge Tour”

Høeg joined fellow contrarians, {like|